Browsing Tag
LAZCLUZE
4 posts
Can J&J’s five-minute NSCLC injection disrupt the EGFR frontline market long ruled by osimertinib?
Johnson & Johnson’s five-minute NSCLC injection RYBREVANT FASPRO wins FDA approval. Learn how this subcutaneous delivery could reshape EGFR frontline therapy.
December 18, 2025
Janssen’s subcutaneous amivantamab gains CHMP backing for EGFR-mutated lung cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a…
February 9, 2025
Johnson & Johnson’s RYBREVANT and LAZCLUZE show unprecedented survival advantage in lung cancer trial
Johnson & Johnson has revealed transformative results from the Phase 3 MARIPOSA clinical trial, positioning the combination of…
January 7, 2025
FDA approves RYBREVANT and LAZCLUZE for EGFR-mutated advanced lung cancer
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as…
August 20, 2024